Trading Sections
Immunome: Regulatory filings and new study data - H.C. Wainwright sees 112% price potential!
ESMO data demonstrate sustainable relief in aggressive desmoid tumors. Analysts see a price target...
Corcept Therapeutics: FDA Decision in December - The Catalyst for the $165 Price Target?
Analysts at Piper Sandler confirm the buy recommendation for Corcept Therapeutics with a price target...
Ionis Pharmaceuticals: Is the RNA specialist poised for a growth phase thanks to Tryngolza potential?
Citi analyst Eric Joseph confirms a price target of Ionis Pharmaceuticals (IONS) of 100 USD and considers...
Climb Bio: Deutsche Bank Identifies Entry Opportunity in Biotech Stock with $28 Price Target
Price target of $28: Why Deutsche Bank currently sees an upside potential of about 185% for Climb Bio....
Annexon: ARCHER-II Readout and GBS Approval - H.C. Wainwright Raises Price Target to 25 USD!
H.C. Wainwright considers the stock of Annexon (ANNX) (i.) to be significantly undervalued and raises...
EchoStar: How the $43 Billion Frequency Deal with SpaceX and AT&T is Realigning the Company
JPMorgan has upgraded the stock of EchoStar (ECHO) to "Overweight" and sees the price target at $144....
Digital Turbine: AI Integration and App Growth Boost Margins - Roth Capital Sees Potential for Doubling Stock Price!
App monetization and AI-driven automation are accelerating the structural growth of Digital Turbine (APPS)...
Sol-Gel Technologies: Topical Skin Cancer Inhibitor in Focus of Wall Street
Cantor Fitzgerald rates the stock as "Overweight" with a target of $200. The analyst points to an attractive...
Electra Therapeutics: Is a price target of 32 USD paving the way for the first FDA approval for mHLH?
The business model focuses on SIRP immunotherapies for inflammatory and oncological diseases. Jefferies...
Nektar Therapeutics: 4.0 Billion USD Revenue Potential – Why a New Biologic Drives the Price Target to 130 USD
Leerink analyst assigns an "Outperform" rating with an ambitious price target of 130 USD for Nektar Therapeutics...
TeraWulf: The Billion-Dollar Infrastructure Transformation for the AI Sector - Morgan Stanley Raises Price Target to $65!
The focus on high-performance computing (HPC) and AI infrastructure fundamentally expands the business...
Vir Biotechnology: FDA Fast Track Status and New Clinical Data as Potential Price Drivers - Barclays Sets Target at $30!
Vir Biotechnology (VIR) focuses on combating infectious diseases and cancer through the human immune...
Chewy Inc.: Analysts from Morgan Stanley see 100% price potential in the subscription model!
Morgan Stanley confirms the buy recommendation for Chewy Inc. (CHWY) with a price target of $36, supported...
Compass Inc.: Anywhere Merger Sparks New Market Enthusiasm - Barclays Sees 70% Price Potential
The technology-based business model of Compass Inc. (COMP) significantly benefits from market consolidation...
Ondas: Drone Defense and Acquisitions Drive the Value of the Autonomy Platform - Citizens Announces $14 Price Target!
Citizens Research has Ondas Inc. (ONDS) initiated coverage on October 5 with an "Outperform" rating...
LB Pharmaceuticals: Targeting a Multibillion-Dollar Market – How a Modified Drug Could Transform Psychiatry
LB Pharmaceuticals (LBRX) is pursuing a new therapeutic approach. LB-102 addresses schizophrenia and...
Kura Oncology: Insider Purchases and Pipeline Expansion as a Catalyst for JPMorgan's $30 Price Target
Kura Oncology (KURA) is making a strategic shift to become a commercial cancer therapeutic provider....
Uranium Energy: Focus on North American Uranium Production Convincing Experts from H.C. Wainwright!
Uranium Energy (UEC) focuses on environmentally friendly in-situ recovery to build a domestic supply...
Syndax Pharmaceuticals: USD 57 Price Target Meets Upcoming MAXPIRe Study Data
Syndax Pharmaceuticals (SNDX) addresses niche markets for immuno-mediated diseases and oncology with...
Lexicon Pharmaceuticals: Strategic Partnerships as a Basis for the Next Valuation Leap?
Cantor Fitzgerald currently rates Lexicon Pharmaceuticals (LXRX) as "Overweight" with a price target...
Adesso: Berenberg sees the stock as a “Multi-Winner” with 135% price potential!
The private bank Berenberg rates the stock of Adesso SE (i.) with a target price of 128 euros as "Buy."...
Praxis Precision Medicines: H.C. Wainwright reaffirms buy recommendation with target of 1201 USD and praises CNS therapies
Praxis Precision Medicines (PRAX) focuses on targeted precision medicine for the treatment of central...
Viking Therapeutics: Oppenheimer sees a price target of $120 - Analysts assign a 90% success chance to the pipeline
Viking Therapeutics (VKTX) focuses on the rapidly growing market for obesity therapies with its dual...